title: Two different classes of therapy-related and de-novo acute myeloid leukemia?
abstract: Two different classes of therapy-related acute myeloid leukemia (t-AML) seem to emerge. One class follows therapy with alkylating agents, increases in frequency with age, often presents with myelodysplasia (MDS), responds poorly to chemotherapy, and shows monosomy 7(-7), monosomy 5(-5), or loss of various parts of the long arms of these chromosomes (5q- and 7q-). The other class is related to therapy with cytostatic drugs targeting at DNA-topoisomerase II, often presents with overt leukemia, responds more favorably to chemotherapy, and shows balanced chromosome aberrations, primarily translocations involving chromosome bands 11q23 and 21q22. These two classes of t-AML may have their counterparts in de-novo acute myeloid leukemia (de-novo AML).
authors.affiliation: Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
authors.forename: J
authors.initials: J
authors.lastname: Pedersen-Bjergaard
authors.forename: P
authors.initials: P
authors.lastname: Philip
mesh_terms: D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002871:Chromosome Banding; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000145:classification / Q000235:genetics*; D009006:Monosomy; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000145:classification / Q000235:genetics*; D016609:Neoplasms, Second Primary; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; D059005:Topoisomerase II Inhibitors